Low-Dose Enoxaparin in Psoriasis

Psoriasis Clinical Trial

Official title: The Efficacy of Low-Dose Enoxaparin in Psoriasis

Status Not yet recruiting

Clinical Trial Summary

Rationale:

• Psoriasis is a chronic immune-mediated inflammatory skin disorder where T cells play a fundamental role in its pathogenesis.

• Low molecular weight heparin has been reported to exert immunomodulatory effect at small doses through inhibition of T cells heparinase enzyme.

• Low molecular weight heparin may have promising results for treatment of psoriasis.

Research question:

• Can low molecular weight heparin be used safely for treatment of psoriasis with good outcome?

• Is enoxaparin inhibitory effect on T cell heparinase enzyme responsible for its beneficial effect?

Hypothesis:

• Low molecular weight heparin can achieve good results when used at small doses for treatment of psoriasis.

• Heparin can exert immunomodulatory effect in psoriasis through inhibition of T cell heparinase enzyme.

AIM OF WORK

-The aim of this work is to assess the possible clinical efficacy and safety of low-dose enoxaparin in the treatment of psoriasis and to detect if inhibition of heparinase enzyme might account for its beneficial therapeutic effect.

Objectives:

• To evaluate safety and efficacy of low molecular weight heparin at small dose for treatment of psoriasis.

• Contribute to the ongoing efforts to optimize psoriasis management and improve the lives of individuals affected by this chronic condition.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Psoriasis

• NCT number: NCT06416566
• Study type: Interventional
• Source: Zagazig University
• Contact: Nourhan Anis
• Phone: +201149947355
• Email: norhan_hn_as@yahoo.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 15, 2024
• Completion date: October 1, 2024